The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

A panelist discusses how recent advances in transurethral resection of bladder tumor (TURBT) include enhanced visualization techniques like fluorescence-guided surgery and narrow-band imaging to ...

"When I eventually met Das at an AUA annual meeting, his smile and demeanor were captivating. I had to push through the hordes of admirers to get close to him," writes Gopal H. Badlani, MD.

Quiz: CUA guidelines on germline genetic testing in prostate cancer ...

Nuclear speckles in ccRCC exist in two states, Signature I and II, affecting tumor behavior and patient outcomes. Signature I is linked to later-stage tumors and poorer outcomes, while Signature II is ...

Quiz: CUA guidelines on germline genetic testing in prostate cancer ...

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says ...

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

"We are now in the golden era of BPH/BPO for both diagnostics and therapeutics," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, shares his thoughts on what advances in benign prostatic ...